Number experiencing adverse effects · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors may leads to higher number of participants experiencing an adverse event compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors leads to higher gastrointestinal adverse effects: diarrhoea compared with placebo (high certainty).
1 finding from 1 review
Psychiatric adverse effects (roflumilast 500 µg) · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors probably leads to higher psychiatric adverse effects (roflumilast 500 µg) compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Asthma exacerbations requiring hospitalisation or a course of steroids · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Change in morning PEF (L/min) at endpoint · people with asthma
It is very uncertain whether atorvastatin changes lung function: change in morning PEF compared with placebo (very low certainty).
1 finding from 1 review
Change from baseline in pre‐bronchodilator FEV1 · people with asthma
It is very uncertain whether atorvastatin changes lung function: change in FEV1 (pre) compared with placebo (very low certainty).
1 finding from 1 review
Lung function: change in FEV1 (post) · people with asthma
It is very uncertain whether atorvastatin changes lung function: change in FEV1 (post) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events or adverse events · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found